NCT01711970 2020-04-24A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian CancerVascular Biogenics Ltd. operating as VBL TherapeuticsPhase 1/2 Completed38 enrolled